Marie Stenmark Askmalm

Summary

Affiliation: University Hospital
Country: Sweden

Publications

  1. ncbi Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients
    Marie Stenmark Askmalm
    Department of Biomedicine and Surgery, Division of Oncology, Faculty of Health, Sciences, Linkoping University, Linkoping, Sweden
    Acta Oncol 43:235-44. 2004
  2. ncbi Altered expression of cyclin E and the retinoblastoma protein influences the effect of adjuvant therapy in breast cancer
    Marie Ahnström Waltersson
    Linkoping University, Faculty of Health Sciences, Department of Clinical and Experimental Medicine, KEF oncology laboratory, University Hospital, SE 581 85 Linkoping, Sweden
    Int J Oncol 34:441-8. 2009
  3. ncbi p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients
    Pia Wegman
    Division of Cell Biology, Department of Biomedicine and Surgery, Faculty of Health Sciences, 581 85 Linkoping, Sweden
    Pharmacogenet Genomics 16:347-51. 2006
  4. ncbi Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer
    Karin Söderlund
    Department of Biomedicine and Surgery, Division of Oncology, Linkoping University, Linkoping, Sweden
    Int J Radiat Oncol Biol Phys 68:50-8. 2007
  5. ncbi Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy
    Patrik Johansson
    Department of Clinical and Experimental Medicine, Linkoping University, Sweden
    Acta Oncol 48:504-13. 2009
  6. ncbi The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer
    Karin Söderlund
    Department of Biomedicine and Surgery, Linkoping University, Linkoping, Sweden
    Radiother Oncol 84:242-51. 2007
  7. ncbi Low expression of Ku70/80, but high expression of DNA-PKcs, predict good response to radiotherapy in early breast cancer
    Karin Söderlund Leifler
    Department of Clinical and Experimental Medicine, Division of Surgery and Clinical Oncology, Linkoping University, Linkoping, Sweden
    Int J Oncol 37:1547-54. 2010

Collaborators

  • Bo Nordenskjold
  • Karin Söderlund
  • Charlotta Dabrosin
  • Pia Wegman
  • Barbro Linderholm
  • O Stal
  • Lars E Rutqvist
  • Karin Söderlund Leifler
  • Tommy Fornander
  • Patrik Johansson
  • Marie Ahnström Waltersson
  • Siv Queseth
  • Rune Gustavsson
  • Peter Skoog
  • Ann Rundcrantz
  • Bedrich Vitak
  • Hans Starkhammar
  • Bengt Asking
  • Harald Bång
  • Annika Malmström
  • Lars Gunnar Arnesson
  • Susanne Vahlin
  • Bengt Norberg
  • Måns Agrup
  • Kerstin Nordenskjöld
  • Claes Klintenberg
  • Lambert Skoog
  • Rebecka Malterling
  • Sten Thorstenson
  • Eibert Einarsson
  • Marie Sundquist
  • Tord Blomkvist
  • Helena Fohlin
  • Göran Tejler
  • Monika Dufmats

Detail Information

Publications7

  1. ncbi Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients
    Marie Stenmark Askmalm
    Department of Biomedicine and Surgery, Division of Oncology, Faculty of Health, Sciences, Linkoping University, Linkoping, Sweden
    Acta Oncol 43:235-44. 2004
    ..Finally, altered p53 status is probably not a marker of resistance to tamoxifen...
  2. ncbi Altered expression of cyclin E and the retinoblastoma protein influences the effect of adjuvant therapy in breast cancer
    Marie Ahnström Waltersson
    Linkoping University, Faculty of Health Sciences, Department of Clinical and Experimental Medicine, KEF oncology laboratory, University Hospital, SE 581 85 Linkoping, Sweden
    Int J Oncol 34:441-8. 2009
    ..17; 95% CI, 0.052-0.58) as compared to patients with either altered Rb or p53 or both (RR=0.70; 95% CI, 0.28-1.73)...
  3. ncbi p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients
    Pia Wegman
    Division of Cell Biology, Department of Biomedicine and Surgery, Faculty of Health Sciences, 581 85 Linkoping, Sweden
    Pharmacogenet Genomics 16:347-51. 2006
    ..The p53 protein is a key determinant to induce either growth arrest or apoptosis in response to cytotoxic stress...
  4. ncbi Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer
    Karin Söderlund
    Department of Biomedicine and Surgery, Division of Oncology, Linkoping University, Linkoping, Sweden
    Int J Radiat Oncol Biol Phys 68:50-8. 2007
    ..To investigate the expression and predictive role of the Mre11/Rad50/Nbs1 (MRN) complex and the ataxia-telangiectasia mutated protein (ATM) for the outcome of radiotherapy in breast cancer patients...
  5. ncbi Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy
    Patrik Johansson
    Department of Clinical and Experimental Medicine, Linkoping University, Sweden
    Acta Oncol 48:504-13. 2009
    ..The aim of this study was to compare the clinical outcome of patients with stage I breast cancer diagnosed during two time periods that differed with respect to adjuvant systemic therapy...
  6. ncbi The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer
    Karin Söderlund
    Department of Biomedicine and Surgery, Linkoping University, Linkoping, Sweden
    Radiother Oncol 84:242-51. 2007
    ..This study evaluates the prognostic and predictive role of BRCA1, BRCA2 and Rad51, individually and as a complex, in breast cancer...
  7. ncbi Low expression of Ku70/80, but high expression of DNA-PKcs, predict good response to radiotherapy in early breast cancer
    Karin Söderlund Leifler
    Department of Clinical and Experimental Medicine, Division of Surgery and Clinical Oncology, Linkoping University, Linkoping, Sweden
    Int J Oncol 37:1547-54. 2010
    ..We believe that the results reflect the different roles of DNA-PKcs and Ku70/80 in repair and cell death regulation after DNA damage. These differences could be of importance when developing drugs that target DNA repair...